Company Overview and News

180
The Alfred E. Mann Foundation for Scientific Research is Pleased to Announce the Appointment of Robert Greenberg, MD, PhD to the Role of Executive Chairman

2018-06-27 accesswire
VALENCIA, CA / ACCESSWIRE / June 27, 2018 / The Alfred E. Mann Foundation for Scientific Research, ''AMF'', an independent non-profit medical device incubator committed to developing and commercializing innovative solutions for significant unmet or poorly met medical conditions, today announced the appointment of Robert Greenberg, MD, PhD to the role of Executive Chairman. ''I have enjoyed interacting with Dr.
BSX EYES PLSE

81
PLSE / Pulse Biosciences, Inc. null

2018-06-24 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0X(# @;V)J#3P\+TQI;F5A
PLSE

81
PLSE / Pulse Biosciences, Inc. null

2018-06-24 sec.gov
SEC Acceleration Request (5-17-2018) May 17, 2018 
PLSE

87
PLSE / Pulse Biosciences, Inc. null

2018-06-18 sec.gov
Form 8-K12B 
PLSE

81
PLSE / Pulse Biosciences, Inc. 8-K (Current Report)

2018-05-28 sec.gov
8K 2018-05-23  UNITED S
PLSE

88
PLSE / Pulse Biosciences, Inc. 424B3 (Prospectus)

2018-05-22 sec.gov
S-3 424 b (3)  Filed Pursuant to Rule 424(b)(3)
PLSE

81
Pulse Biosciences' (PLSE) CEO Darrin Uecker on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Good afternoon. My name is Julie and I will be your conference operator today. At this time, I would like to welcome everyone to the Pulse Biosciences Investor Update Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session [Operator Instructions].
COMD PLSE

102
PLSE / Pulse Biosciences, Inc. S-3

2018-05-09 sec.gov
S-3 As filed with the Securities and Exchange Commission on May 9, 2018 Registration No. 333- &nb
PLSE

86
PLSE / Pulse Biosciences, Inc. 8-K (Current Report)

2018-05-08 sec.gov
8-K (5-8-2018) 
PLSE

83
PLSE / Pulse Biosciences, Inc. 10-Q (Quarterly Report)

2018-05-08 sec.gov
20180331- Q1  
PLSE

81
PLSE / Pulse Biosciences, Inc. / Strome Mark E - SC 13G (Passive Investment)

2018-05-01 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934
PLSE

85
PLSE / Pulse Biosciences, Inc. / Strome Mark E - SC 13G (Passive Investment)

2018-05-01 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934
PLSE

83
Pulse Biosciences: Failed FDA Clearance, New SEC Investigation, And An Uncertain Path Forward

2018-04-24 seekingalpha
Pulse failed to achieve an FDA 510(k) clearance which it had previously described as a “foundation for future clearances”. The current direction of the company seems highly uncertain.
PLSE

114
Biotech Analysis Central Pharma News: GlaxoSmithKline Passes Along Pipeline, Pulse Impresses, Celldex's Failure

2018-04-17 seekingalpha
GlaxoSmithKline hands over rare disease unit over to Orchard Therapeutics in exchange for a 19.99% stake and board seat.
CLDX GSK PLSE GSK

PLSE: Pulse Biosciences Analysis and Research Report

2018-02-19 - Asif

Pulse Biosciences is a clinical-stage medical technology company developing a non-thermal tissue treatment platform technology based upon its proprietary Nano-Pulse Stimulation (“NPS”) technology and pursuing applications in oncology, dermatology, general tissue treatment and veterinary medicine. NPS is a novel patented technology which leverages nano-second duration energy pulses that have demonstrated effective local tumor control and the initiation of an adaptive immune response in pre-clinical studies. Pulse Biosciences is pursuing a number of clinical applications for NPS, including oncology, dermatology, aesthetics and other minimally invasive applications where the company believe NPS has the potential to compare favorably with current therapies and treatments. Pulse Biosciences is currently conducting research and development activities in pursuit of commercial applications for its NPS technology, but Pulse Biosciences has not yet commercialized or recognized revenue from its t...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

22h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

23h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to PLSE / Pulse Biosciences, Inc. on message board site Silicon Investor.

premier laser sys inc (plsia new plsea.o)
CUSIP: 74587B101